Zacks’ Voice of the People Highlights user AndrewGreenBull: “PDEX: Profitability Will Be Key to Success” from the People & Picks community.

For more Voice of the People, visit

Featured Post

PDEX: Profitability Will Be Key to Success

People who are familiar with the healthcare sector might have found a different phenomenon in the New Year that investors start switching their focus on companies which have cutting edge products and long-term profitability, like Heska Corp. (HSKA) and Angiotech Pharma (ANPI).

HSKA has had more than 100% gains since last December and kept challenging $1 resistance in the past week. The stock price is still attractive at this level in view of its prospect; Although ANPI missed expectation for last quarter’s earning, it still has a 15% gain after my introduction. This reflected investors’ confidence on the company’s products and sales ability. I still will keep it on the top of my watch list.

Another stock which has similar situation to HSKA and ANPI is PDEX. If you make a comparison between PDEX and HSKA, you will find out that PDEX is a perfect replica of HSKA. If I have to tell a difference, then I think PDEX is undervalued more.

About Pro-Dex, Inc. (PDEX)

PDEX specializes in the development and manufacture of technology-based solutions that incorporate embedded motion control, miniature rotary drive systems, and fractional horsepower DC motors, serving the medical, dental, semiconductor, scientific research and aerospace markets.

The company’s products are used in hospitals, dental offices, medical engineering labs, scientific research facilities and high tech manufacturing operations around the world.

PDEX, like other small cap companies in the healthcare sector, was severely impacted in the worldwide economic crisis. The Market is gradually warming up, so are PDEX’s product sales. The odd thing is that its stock price didn’t rebound with the market. From the volumes in the last several months, we can tell that it is staying in a forgotten corner.

But I believe that PDEX’s stock price will catch up with the market soon, not only because that it is undervalued, but also because that some catalysts are coming near.

About the Zacks Community

In 2008, Zacks Investment Research launched, a stock-picking website where members of the Zacks community can test their strategies and share ideas with other members. Each user is scored on the accuracy of his or her picks, and top users are rewarded with free products from Zacks. Registration is free. To learn more visit

About Zacks is a property of Zacks Investment Research, Inc., which was formed in 1978 by Leonard Zacks. As a PhD in mathematics Len knew he could find patterns in stock market data that would lead to superior investment results. Amongst his many accomplishments was the formation of his proprietary stock picking system; the Zacks Rank, which continues to outperform the market by nearly a 3:1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter; Profit from the Pros.  In short, it’s your steady flow of Profitable ideas GUARANTEED to be worth your time! Register for your free subscription to Profit From the Pros by going to

Follow us on Twitter:

Join us on Facebook: 

Visit for information about the performance numbers displayed in this press release.
Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.

Disclaimer: Past performance does not guarantee future results. Investors should always research companies and securities before making any investments. Nothing herein should be construed as an offer or solicitation to buy or sell any security.

Contact: Devin Weiss
Syndication Manager
Phone: 312-265-9491

Zacks Investment Research